Abram Scientific wins up to $8.3M from DARPA for a handheld coagulation test

MedDevice Startups Staff · Oct 13 · 2 min read · Via PR Newswire

DARPA awarded Abram Scientific a contract worth up to $8.3M to develop its CoagCare coagulation system for military trauma care. The Menlo Park company announced the award on October 13. It received a $2M DARPA contract in October 2025 to miniaturize the system.

CoagCare is a compact meter that runs a single-use test card. It measures the viscoelastic properties and density of whole blood from one drop, and characterizes clot formation through lysis in under 10 minutes. The money covers optimization for the DARPA RAPIID program, manufacturing capacity and a military-focused design. RAPIID stands for Resuscitation and Prevention of Ischemia-Induced Dysfunction, and pairs a shelf-stable blood analog with point-of-care diagnostics.

CoagCare is not FDA cleared. Abram Scientific raised an $11.75M Series A led by Octapharma AG in February 2026 and said it would pursue a 510(k) for civilian transfusion management. Non-dilutive defense money that pays for manufacturing capacity is the useful kind, because it funds the line item equity investors discount hardest.

Questions & Answers

How much did Abram Scientific receive from DARPA?

DARPA awarded Abram Scientific a contract worth up to $8.3 million, announced October 13, 2026. It follows a $2 million DARPA contract the company received in October 2025.

What is the Abram Scientific CoagCare system?

CoagCare is a handheld point-of-care system from Abram Scientific. It measures the viscoelastic properties and density of whole blood from a single drop, characterizing coagulation from clot formation through lysis in under 10 minutes.

Is Abram Scientific's CoagCare FDA cleared?

No. Abram Scientific says CoagCare is not yet cleared by FDA for marketing in the United States. The company has said it intends to pursue 510(k) clearance for civilian transfusion management.

← Back to Fundraising